Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frances A Shepherd

Showing results (191-200 of 384) with videos related to

Pageof 39
Sort By:
Clinical Lung Cancer|March 2, 2016
Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse ModelPetra Martin, Erin Stewart, Nhu-An Pham, et al.
JTO Clinical and Research Reports|February 3, 2022
Effects of Ethnicity on Outcomes of Patients With <i>EGFR</i> Mutation-Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical ResectionMike R Sung, Pascale Tomasini, Lisa W Le, et al.
Experimental Hematology & Oncology|November 22, 2014
Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trialTeresa Moran, Enriqueta Felip, Vicki Keedy, et al.
Biotechnology Annual Review|October 12, 2005
A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphomaCarol Anne Sawka, Frances A Shepherd, Edmee Franssen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancerHelen J Ross, George R Blumenschein, Joseph Aisner, et al.
Clinical Lung Cancer|May 28, 2018
Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung CancerAlona Zer, Mike R Sung, Preet Walia, et al.
Oncotarget|June 2, 2018
Lung cancer in never smokers from the Princess Margaret Cancer CentreGrzegorz J Korpanty, Suzanne Kamel-Reid, Melania Pintilie, et al.
Clinical Lung Cancer|February 17, 2019
Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung CancerPascale Tomasini, Celine Mascaux, Kevin Jao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 19, 2022
Single-Cell Analysis Reveals Transcriptomic Features of Drug-Tolerant Persisters and Stromal Adaptation in a Patient-Derived EGFR-Mutated Lung Adenocarcinoma Xenograft ModelNadeem Moghal, Quan Li, Erin L Stewart, et al.
Lung Cancer (Amsterdam, Netherlands)|December 18, 2004
Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: final results of the Toronto phase II trialRonald L Burkes, Frances A Shepherd, Martin E Blackstein, et al.
Pageof 39

Showing results (191-200 of 384) with videos related to

Sort By:
Pageof 39
Clinical Lung Cancer|March 2, 2016
Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse ModelPetra Martin, Erin Stewart, Nhu-An Pham, et al.
JTO Clinical and Research Reports|February 3, 2022
Effects of Ethnicity on Outcomes of Patients With <i>EGFR</i> Mutation-Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical ResectionMike R Sung, Pascale Tomasini, Lisa W Le, et al.
Experimental Hematology & Oncology|November 22, 2014
Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trialTeresa Moran, Enriqueta Felip, Vicki Keedy, et al.
Biotechnology Annual Review|October 12, 2005
A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphomaCarol Anne Sawka, Frances A Shepherd, Edmee Franssen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancerHelen J Ross, George R Blumenschein, Joseph Aisner, et al.
Clinical Lung Cancer|May 28, 2018
Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung CancerAlona Zer, Mike R Sung, Preet Walia, et al.
Oncotarget|June 2, 2018
Lung cancer in never smokers from the Princess Margaret Cancer CentreGrzegorz J Korpanty, Suzanne Kamel-Reid, Melania Pintilie, et al.
Clinical Lung Cancer|February 17, 2019
Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung CancerPascale Tomasini, Celine Mascaux, Kevin Jao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 19, 2022
Single-Cell Analysis Reveals Transcriptomic Features of Drug-Tolerant Persisters and Stromal Adaptation in a Patient-Derived EGFR-Mutated Lung Adenocarcinoma Xenograft ModelNadeem Moghal, Quan Li, Erin L Stewart, et al.
Lung Cancer (Amsterdam, Netherlands)|December 18, 2004
Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: final results of the Toronto phase II trialRonald L Burkes, Frances A Shepherd, Martin E Blackstein, et al.
Pageof 39